On July 7, Kailera Therapeutics announced that its GLP-1 drug for diabetes and obesity met the primary endpoints in two late-stage trials. On the same day, the U.S. Food and Drug Administration approved Vera Therapeutics' drug to treat a potentially life-threatening kidney disease. On July 9, Dr. Reddy's Laboratories announced a delay in commercial supplies of semaglutide due to an issue with the active pharmaceutical ingredient.
Torrent Pharmaceuticals initiates a voluntary recall of Semalix pens following a manufacturing defect notice from supplier Dr. Reddy's.
Read the full storyThe Indian pharmaceutical firm postponed the commercial launch of its weight-loss drug version due to active pharmaceutical ingredient issues, impacting near-term revenue projections.
Kailera Therapeutics announced its GLP-1 drug met primary endpoints in two late-stage trials, positioning the company to compete in the surging weight-loss and diabetes market.